

## The Diarylheptanoid (+)-aR,11S-Myricanol and Two Flavones from Bayberry (*Myrica cerifera*) Destabilize the Microtubule-Associated Protein Tau

Jeffrey R. Jones,<sup>†,‡</sup> Matthew D. Lebar,<sup>§,⊥</sup> Umesh K. Jinwal,<sup>†,‡</sup> Jose F. Abisambra,<sup>†,‡</sup> John Koren III,<sup>†,‡</sup> Laura Blair,<sup>†,‡</sup> John C. O'Leary,<sup>†,‡</sup> Zachary Davey,<sup>†,‡</sup> Justin Trotter,<sup>‡,||</sup> Amelia G. Johnson,<sup>†,‡</sup> Edwin Weeber,<sup>‡,||</sup> Christopher B. Eckman,<sup>∇</sup> Bill J. Baker,<sup>\*,⊥</sup> and Chad A. Dickey<sup>\*,†,‡</sup>

Department of Molecular Medicine, Department of Molecular Pharmacology and Physiology, and Alzheimer's Institute, University of South Florida, Tampa, Florida 33613, United States, Department of Chemistry and Center for Molecular Diversity in Drug Design, Discovery and Delivery, University of South Florida, Tampa, Florida 33620, United States, and Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, United States

Received August 13, 2010

Target-based drug discovery for Alzheimer's disease (AD) centered on modulation of the amyloid  $\beta$  peptide has met with limited success. Therefore, recent efforts have focused on targeting the microtubule-associated protein tau. Tau pathologically accumulates in more than 15 neurodegenerative diseases and is most closely linked with postsymptomatic progression in AD. We endeavored to identify compounds that decrease tau stability rather than prevent its aggregation. An extract from *Myrica cerifera* (bayberry/southern wax myrtle) potently reduced both endogenous and overexpressed tau protein levels in cells and murine brain slices. The bayberry flavonoids myricetin and myricitrin were confirmed to contribute to this potency, but a diarylheptanoid, myricanol, was the most effective anti-tau component in the extract, with potency approaching the best targeted lead therapies. (+)-aR,11S-Myricanol, isolated from *M. cerifera* and reported here for the first time as the naturally occurring aglycone, was significantly more potent than commercially available ( $\pm$ )-myricanol. Myricanol may represent a novel scaffold for drug development efforts targeting tau turnover in AD.

Targeting the microtubule-associated protein tau (MAPT) that pathologically accumulates in Alzheimer's disease (AD) has emerged as perhaps the most effective strategy for treating postsymptomatic AD.<sup>1–8</sup> Tau normally functions to stabilize microtubules in neurons, but in disease it pathologically aggregates in AD and other tauopathies.<sup>9–14</sup> Tau forms neurofibrillary tangles (NFTs), which are intracellular aggregates composed of paired helical filaments (PHFs) of the tau protein.<sup>15,16</sup> While aggregation of tau into tangles is indeed the strongest post-mortem correlate of disease severity, tau intermediates may be more neurotoxic than higher order aggregates. It was long thought that the NFTs impair synaptic plasticity and cognitive function;<sup>17</sup> however, it is now clear that soluble tau intermediates, rather than pathologically visible aggregates, are responsible for the cognitive dysfunction in AD and other tauopathies.<sup>6–8,18</sup> Thus, while a number of efforts are underway to prevent tau aggregation,<sup>19,20</sup> approaches to enhance tau turnover are less advanced.<sup>21</sup> Our goal is to fill this void in the AD drug development pipeline. While reducing all tau in cells would likely lead to toxicity, we speculated that removing some tau from a symptomatic AD brain may be an effective therapeutic strategy. Moreover, normal, functional tau is less affected by clearance pathways in the cell than aberrant tau, suggesting that modulators of tau clearance may selectively target abnormal tau.<sup>21,22</sup>

Natural products chemistry has produced several effective AD therapy leads, including the amyloid aggregation inhibitor curcumin, isolated from tumeric,<sup>23</sup> the microtubule stabilizer paclitaxel from the Pacific yew tree,<sup>24</sup> and the *Streptomyces*-derived Hsp90 inhibitor geldanamycin.<sup>21</sup> By analyzing extracts from natural sources with a modern cell-based screening platform that measures tau levels,<sup>25–27</sup> we found that bayberry (*Myrica cerifera*) extract potently enhanced

tau clearance. Fractionation of this extract revealed (+)-aR,11S-myricanol, a novel AD scaffold that could be used to develop future compounds to reduce tau burden.

### Results and Discussion

**Cell-Based Natural Product Screen Identifies Bayberry Extract as Potent Tau Reducer.** A small natural product library was screened for anti-tau efficacy. M17 neuroblastoma cells were treated for 24 h, and an In-Cell Western (ICW) screen was performed to assess tau and GAPDH levels. This cell line is derived from striatal neurons and has high levels of endogenous tau. The results from 10 random extracts, in triplicate, are shown in Figure 1A. Wells lacking a GAPDH signal suggest toxicity. The entire assay was performed in a total of 10 plates. Analysis of this screen revealed that extract from *M. cerifera* (bayberry extract, Herb Pharm) was the most potent tau reducer lacking cellular toxicity (Figure 1B).

Anti-tau efficacy using immunocytochemistry was then confirmed in a second neural cell line, H4 neuroglioma cells. H4 cells were chosen for secondary analysis not only because they have high levels of endogenous tau similar to M17 cells but also because they are also more adherent compared to M17 cells, making them very well-suited for fluorescent immunocytochemistry (Figure 2). H4 cells were treated with indicated amounts of bayberry extract. After 24 h, immunofluorescent staining showed a dose-dependent decrease in tau levels (Figure 2). No toxicity was observed with LDH release analyses (data not shown).

**Bayberry Aqueous Extract Reduces Tau Levels in a Cell Model That Overexpresses Tau As Well As a Cell Line Derived from Hippocampal Neurons.** Raw bayberry root-bark powder was extracted in pure water, resulting in a solution that contained 7 mg extract/mL solution. A HeLa cell line stably transfected with tau (HeLa-C3) and a human IMR32 cell line derived from hippocampal neurons were then treated with the indicated doses (Figure 3A and B, respectively) for four hours to assess the effects of the aqueous extract on both overexpressed and endogenous tau levels. The hippocampus is the region first affected by tau deposition in Alzheimer's disease. Indeed, tau was reduced

\* To whom correspondence should be addressed. E-mail: cdickey@health.usf.edu; bjbaker@usf.edu.

<sup>†</sup> Department of Molecular Medicine, University of South Florida.


<sup>‡</sup> Alzheimer's Institute, University of South Florida.

<sup>§</sup> Co-first author.


<sup>⊥</sup> Department of Chemistry and Center for Molecular Diversity in Drug Design, Discovery and Delivery, University of South Florida.

<sup>||</sup> Department of Molecular Pharmacology and Physiology, University of South Florida.

<sup>∇</sup> Department of Neuroscience, Mayo Clinic.



**Figure 1.** M17 cells were plated in 96-well plates and treated with 190 extracts (10%/vol, Herb Pharm) for 24 h. An ICW was used to identify extracts capable of reducing tau levels relative to GAPDH. Example of a result with 10 extracts is shown (A). Bayberry extract was identified as the most potent tau reducer with no toxicity (B). Toxicity was determined by calculating GAPDH levels relative to vehicle.



**Figure 2.** H4 neuroglioma cells in four-well chamber slides were treated with the indicated amounts of bayberry extract from Herb Pharm (mixed suspension with ethanol, glycerol, and water) for 24 h and fixed, and tau immunoreactivity was assessed using standard (as opposed to near-infrared) immunofluorescent microscopy. Quantitation was derived using optical density with ImageJ software.


in both cell lines by  $\sim 60\%$  when treated with  $70 \mu\text{g/mL}$  aqueous extract (Figure 3C). Thus bayberry extract was capable of reducing tau levels in three brain-derived cell lines as well as a cell line overexpressing tau.

**Bayberry Aqueous Extract Significantly Reduces Tau Levels in Fresh Forebrain Tissue Slices Derived from Mice.** Acute murine brain slices from wild-type mice were treated with the aqueous preparation at six doses ( $9\text{--}140 \mu\text{g/mL}$ , Figure 4A) for four hours, as previously described.<sup>28</sup> Total and phospho-tau levels were reduced by as much as 40%, reaching statistical significance at doses  $> 70 \mu\text{g/mL}$  by volume (Figure 4B).

**Fractionation of Bayberry Reveals Both Novel and Previously Described Tau-Reducing Compounds.** Ethanol extraction and fractionation of *M. cerifera* was carried out to identify the constituents<sup>29–32</sup> of bayberry that were primary contributors to the observed effects on tau levels. HeLa-C3 cells were used to confirm that crude EtOH extraction did not reduce the potency of the bayberry extract. Cells were treated with indicated concentrations of the EtOH extract of bayberry for four hours, and tau levels were assessed by Western blot. Tau levels were dose dependently reduced at all concentrations, showing similar potency to the aqueous extract


(Figure 5A). The EtOH extract was subjected to acid hydrolysis to enrich the aglycone component of the extract, then fractionated via MPLC. Treatment of HeLa-C3 cells with  $400 \mu\text{g/mL}$  of each UV-active fraction from the hydrolyzed EtOH extract showed that the eighth fraction (F8) had the most anti-tau potency (Figure 5B). Even though other fractions lacked the same potency as F8, many of the fractions could reduce tau levels (Figure 5C). For example, despite modest reductions, LC/MS demonstrated that F11 contained the known tau-reducing compound myricetin, while fraction F8 contained a novel tau modifier, the diarylheptanoid myricanol.

**Rhamnosidation of the Known Tau Reducer Myricetin Does Not Improve Anti-tau Efficacy.** TLC analysis of crude hydrolyzed bayberry extract demonstrated that the aglycone myricetin was present when analyzed concurrently with commercially available myricetin. Myricetin was previously shown to be both a major constituent of bayberry after acid hydrolysis<sup>31</sup> and an inhibitor of Hsp70 ATPase activity that reduced tau levels.<sup>28</sup> Myricitrin (**1**), a rhamnoside of the flavonoid myricetin (**2**), has been found in high concentration in bayberry.<sup>33</sup>




Since flavonoids typically have poor bioavailability, we speculated that myricitrin might be more effective given the addition of the carbohydrate moiety.<sup>34</sup> A time course study was performed using commercially available myricitrin and myricetin. We tested the anti-tau efficacy of each over a 24 h period in HeLa-C3 cells (Figure 6A and B) and found that both myricitrin and myricetin showed similar activity (Figure 6C). Thus, myricetin efficacy could not be improved by rhamnosidation.


**The Diarylheptanoid Myricanol Has Unique Structural Properties Compared to That Extracted from Other Species.** The primary constituent of F8 was found to be myricanol (**3**), a diarylheptanoid. Both <sup>1</sup>H and <sup>13</sup>C NMR data are in agreement with recently published data,<sup>35,36</sup> but differ from those NMR data published earlier.<sup>37</sup> Interestingly, the specific rotation for myricanol isolated in this study ( $[\alpha]_D^{20} = +48.0$ ) differed in sign from previous reports:  $[\alpha]_D^{27.5} = -65.6$  from *M. nagi*;<sup>38</sup>  $[\alpha]_D = -62.9$  from *M. rubra*;<sup>39</sup>  $[\alpha]_D^{22} = -27.6$  from *M. rubra*;<sup>40</sup>



**Figure 3.** HeLa cells stably overexpressing tau (HeLa-C3; A) and IMR32 cells with endogenous tau levels (B) were treated for 4 h with an aqueous bayberry extract at 0–70 μg/mL. Quantification of the Western blots after actin normalization displays a downward trend in tau levels. Tau levels are shown as a percentage of vehicle-treated cells ± SD (C).




**Figure 4.** Representative Western blot (A) is used to demonstrate the dose-dependent reductions in tau levels from whole brain murine slice cultures obtained from four wild-type mice (2 males, 2 females) at 5 months of age. Treatments were performed in duplicate at indicated μg/mL doses for each mouse. Each point in the graph to the right (B) represents the average tau reductions ( $n = 8$  slices) for all four mice at the given doses relative to the average vehicle ± SD \* $p < 0.05$  by Student's  $t$  test.




**Figure 5.** Bayberry ethanol extract displays anti-tau activity (A). Eight UV-active chromatographic fractions from the hydrolyzed bayberry extract were tested on HeLa-C3 cells. The cells were treated with 400 μg/mL of each UV-active bayberry fraction for 4 h and analyzed by Western blot (B). Tau reductions are presented in the graph (C) as a percentage of vehicle-treated cells (dashed line) ± SD.

$[\alpha]_D = -64.0$  from *M. esculenta*,<sup>37</sup> and  $[\alpha]_D = 0.0$  from *M. cerifera*.<sup>35</sup> All previously isolated myricanol displayed negative rotations with the exception of one racemate. The negative

rotation was correlated to an 11R configuration via X-ray crystallography of a brominated derivative of myricanol.<sup>38</sup> (–)-*R*-Myricanol from *M. rubra* ( $[\alpha]_D^{24} = -48.3$ ) along with (+)-




**Figure 6.** Commercial myricitrin (50 μM, DMSO) and myricetin (50 μM, DMSO) were tested over time on HeLa-C3 cells (A and B). The results are displayed as a trend line of tau levels as a percent of vehicle ± SD (C).



**Figure 7.** Extracted myricanol was used to treat HeLa-C3 cells that overexpress tau, O.E., (A) IMR32 cells that express endogenous (endo) tau (B), and murine brain slices (C). The Western blot results were quantified and plotted as a percent of vehicle ± SD (D).

*S*-myricanol 5-*O*-β-*D*-glucopyranoside, which, upon hydrolysis yielded (+)-*S*-myricanol ( $[\alpha]_{D}^{22} = +37.3$ ), have been reported<sup>41</sup> with the 11*S* configuration, confirmed by Mosher's analysis. The <sup>1</sup>H and <sup>13</sup>C NMR data as well as the rotation reported for the hydrolyzed product matched those of the myricanol isolated in this study. The CD spectrum of our (+)-*S*-myricanol displayed positive Cotton effects that mirror the negative Cotton effects previously reported for (–)-*R*-myricanol,<sup>38,40</sup> confirming our isolate has not only an 11*S* configuration but also equal and opposite biphenyl twisting. Joshi et al.<sup>35</sup> reported an X-ray structure of the enantiomeric pair of (+)-*aR*,11*S*- and (–)-*aS*,11*R*-myricanol and also noted that the crystal structure of (–)-*aS*,11*R*-myricanol closely resembled that of the previously reported brominated derivative of 11*R*-myricanol isolated by Begley et al.<sup>38</sup> We surmise, from the identical NMR data shared by our compound and both the racemate isolated by Joshi et al. and the 11*S*-aglycone obtained by Matsuda et al.<sup>41</sup> as well as the inverse CD spectra and specific rotations of our compound and (–)-*aS*,11*R*-myricanol reported by Begley et al., that we have in fact isolated (+)-*aR*,11*S*-myricanol. (+)-11*S*-Myricanol has been identified previously as a glycoside<sup>41</sup> and part of a racemic mixture,<sup>35</sup> but the aglycone of the (+)-11*S*-enantiomer had not previously been found to occur naturally.



**(+)-3:** (+)-*aR*,11*S*-myricanol


### Myricanol Is a Potent Tau Modulator in Several Models, Including Brain Tissue.

(+)-*aR*,11*S*-Myricanol was used to treat HeLa-C3 cells (Figure 7A), IMR32 hippocampus-derived cells (Figure 7B), and murine brain slices (Figure 7C). (+)-*aR*,11*S*-Myricanol potently reduced tau levels in all models with comparable potency (Figure 7D). No toxicity was observed by a lactate dehydrogenase release assay (data not shown).

### Chirality Significantly Contributes to the Anti-tau Efficacy of Myricanol.

Due to inconsistencies noted above in specific rotations, chiral HPLC analysis was conducted and revealed that our isolate was not enantiopure but, in fact, a scalemic mixture (86% ee, Figure 8A; racemic myricanol is shown for comparison in 8B). Investigation of tau levels in HeLa-C3 cells treated with the indicated concentrations of the isolated (+)-*aR*,11*S*-myricanol (86% ee) and commercially available “racemic” myricanol (actually





**Figure 8.** Using a chiral stationary phase, HPLC traces of (+)-aR,11S-myricanol from *M. cerifera* (A) and commercially available ( $\pm$ )-myricanol (B) reveal 86% and 9% ee, respectively. Tau levels in HeLa-C3 cells are reduced significantly by enantiomerically enriched (+)-aR,11S-myricanol, but the racemic mixture showed no activity at similar concentrations (C and D).

9% ee) showed that only the isolated myricanol reduced tau levels (Figure 8C): The  $EC_{50}$  of (+)-aR,11S-myricanol (86% ee) was  $\sim 35$   $\mu$ M (Figure 8D). Thus, (+)-aR,11S-myricanol isolated from *M. cerifera* may represent a novel scaffold from the diarylheptanoid family that drives tau reductions based on chirality.

Natural product-based drug discovery has yielded a number of promising compounds that are in clinical and preclinical development for AD and other neurodegenerative diseases. An extract from *M. cerifera* was shown to decrease tau levels in several cell models as well as murine brain slices. Three compounds capable of reducing tau levels were identified from this extract: myricetin, myricitrin, and (+)-aR,11S-myricanol. Myricetin is a flavonoid found in the root bark of *M. cerifera*. In nature, it exists as the glycoside myricitrin and has been isolated in quantities of up to 2.5 g/kg.<sup>33</sup> We have shown here that both myricetin and its “pro-drug” myricitrin reduce tau levels. Indeed, it is likely that myricitrin does function as a pro-drug *in vivo* due to the activity of glycoside hydrolases that are especially prevalent in the intestinal tract. Myricitrin is more stable in DMSO and more water-soluble than myricetin. This could have implications for therapeutic efforts focused on flavonoid-based drug development. Flavonoids, and other antioxidants in general, have been the focus of intensive research efforts in AD and other neurodegenerative diseases. The antioxidant properties of flavonoids help to prevent oxidation of crucial proteins and biomolecules. The flavonoids quercetin and epigallocatechin gallate have demonstrated efficacy for preventing various aspects of AD pathogenesis.<sup>42–46</sup> While flavonoids are attractive from a biological standpoint, their development into robust therapeutics has been hampered by their inherent lack of stability.<sup>27,47</sup>

Because the literature suggested that the primary component of bayberry was myricetin in the form of myricitrin, we were initially resolved to attribute the anti-tau efficacy of bayberry to these flavonoids. Surprisingly, however, the most potent anti-tau compound extracted from bayberry was not a flavonoid, but rather the diarylheptanoid myricanol, which has not previously been shown to have efficacy for AD or other tauopathies. This family of compounds also includes curcumin, an extensively studied anti-inflammatory and antiamyloidogenic agent.<sup>23</sup> In fact, curcumin can also modulate tau phosphorylation in cultured hippocampal neurons.<sup>48</sup> These structural similarities between curcumin and myricanol may allow for faster elucidation of the mechanism of action for myricanol. Although both compounds are diarylheptanoids, curcumin is linear, while myricanol possesses a *meta–meta*-bridged

macrocyclic structure. Also, this is the first description of the dextrorotatory aglycone ((+)-aR,11S-myricanol) being found in nature or derived synthetically,<sup>49</sup> and it is this enantiomer that seems to possess anti-tau efficacy with a potency commensurate with previously characterized targeted therapeutic lead compounds.<sup>21,28</sup> Thus, (+)-aR,11S-myricanol is a novel and potentially highly tractable drug scaffold. The physical properties of myricanol suggest that it will abide by Lipinski’s rule of five and could serve as the foundation for new and potent anti-tau therapies.

## Experimental Section

**Analytical Instrumentation.** Specific rotations were measured on an Autopol IV automatic polarimeter using a Na lamp corrected to 20 °C. UV data were obtained on a Varian Cary 50-Bio UV–visible spectrophotometer using a xenon lamp. Circular dichroism (CD) spectra were obtained with an Aviv Instruments model 215 CD spectrometer using a xenon lamp. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian 400 MHz spectrometer using residual protonated solvent as <sup>1</sup>H internal standard or <sup>13</sup>C absorption lines of solvents for <sup>13</sup>C internal standard. NMR data were obtained in CDCl<sub>3</sub> (purchased from Cambridge Isotope Laboratories). LC/MS data were obtained on an Agilent 1100 LC/MS TOF ESI mass spectrometer. Separations were conducted on a Teledyne Isco Combiflash Companion MPLC instrument using an appropriately sized normal-phase silica gel cartridge purchased from Teledyne Isco. Enantiomeric excess was measured via HPLC (Shimadzu Prominence LC-20AT HPLC system with a SPD-N20A diode array detector using a Whelk-O 1 column, solvent system: 5% IPA/hexanes, 0.8 mL/min.).

**Antibodies and Reagents.** Anti-tau antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and Dako (Carpinteria, CA). Anti-actin and anti-GAPDH were purchased from Sigma Aldrich and Biodesign (Birmingham, AL). All of these aforementioned antibodies were used at a dilution of 1:1000. Anti-S396/S404 phosphorylated tau antibody (pS396/404) was used at a dilution of 1:200 and was provided by P. Davies, Albert Einstein College of Medicine (New York, NY). Secondary antibodies were purchased from Southern Biotech (Birmingham, AL) and used at a 1:1000 dilution. Fluorescent secondary antibodies were purchased from Molecular Probes and Rockland Laboratories. All antibodies were diluted into 7% nonfat dry milk (Bio-Rad Laboratories) in TBS. Myricitrin and ( $\pm$ )-myricanol were purchased from Indofine Chemical Company, Inc. (Hillsborough, NJ). Myricetin was purchased from Sigma-Aldrich. These compounds were all solubilized in DMSO to 50 mM.

**Aqueous Extract of Bayberry.** Bayberry root-bark powder was purchased from Frontier Natural Products Co-op (Norway, IA). An aqueous extract was prepared fresh for each experiment by adding 400 mg of root-bark powder to 10 mL of deionized H<sub>2</sub>O. The solution was

protected from light and allowed to nutate at room temperature for 1 h, after which it was centrifuged at 4200 rpm for 15 min to remove insoluble particles. The liquid was lyophilized to determine the concentration of dissolved analytes (7 mg/mL).

**Lipophilic Extract of Bayberry and Isolation of (+)-aR,11S-Myricanol.** Raw-bayberry root-bark powder (50 g) was extracted with 150 mL of toluene under agitation for 6 h in a flask protected from light. The filtrate was concentrated, and the marc was then extracted under agitation with 150 mL of 95% EtOH for 6 h, again protected from light. The EtOH extract was dried *in vacuo*, yielding 5.6 g of crude extract. Acid hydrolysis was performed on 2 g of EtOH extract to facilitate the conversion of myricitrin to myricetin<sup>31</sup> by refluxing for 2 h in 16 mL 1:1 MeOH/aqueous HCl (1.2 M) with addition of *tert*-butylhydroquinone (TBHQ) (32 mg) as an antioxidant. The mixture was then concentrated *in vacuo* and fractionated on a silica gel column using MPLC (silica cartridge, Isco Combiflash Companion) with a linear gradient of 0–20% MeOH/CHCl<sub>3</sub> (0.1% TFA). Fraction 8 (F8) was further purified on MPLC (silica, eluting with a linear gradient of 40–45% EtOAc/hexanes) to afford (+)-aR,11S-myricanol (12 mg). The previously prepared toluene extract was concentrated and found to be a mixture of compounds (~1.4 g) with (+)-aR,11S-myricanol as the major constituent. A portion of the toluene extract was purified (430 mg) using silica gel MPLC, eluting at 40% EtOAc/hexanes to yield 180 mg of (+)-S-myricanol: 86% ee;  $[\alpha]_D^{20} = +48.0$  (*c* 1.0, CHCl<sub>3</sub>); UV  $\lambda_{max}$  nm (MeOH) 215, 220, 260, 300; CD  $\lambda_{max}$  nm (MeOH) ( $\Delta\epsilon$ ) 238 (+5.6), 258 (+6.1), 301 (+4.9); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  (integration, multiplicity, J (Hz), position): 1.50–1.62 (3H, m, OH11, H9a, H10a), 1.63–1.77 (2H, m, H9b, H12a), 1.89–1.99 (3H, m, H<sub>2</sub>8, H10b), 2.35 (1H, m, 12b), 2.56 (1H, m, H7a), 2.81 (1H, dt, 18.2, 3.0, H7b), 2.93 (2H, m, H<sub>2</sub>13), 3.89 (3H, s, H<sub>3</sub>20), 4.01 (3H, s, H<sub>3</sub>21), 4.10 (1H, t, 9.8, H11), 5.87 (1H, br s, OH5), 6.92 (1H, s, H19), 6.92 (1H, d, 8.1, H16), 7.10 (1H, dd, 8.1, 2.0, H15), 7.19 (1H, d, 2.0, H18), 7.68 (1H, s, OH17); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  (position) 22.9 (C9), 25.4 (C7), 25.8 (C8), 26.9 (C13), 34.7 (C12), 39.4 (C10), 61.4 (C2, C20 and C21), 68.6 (C11), 116.8 (C16), 122.6 (C6), 123.4 (C2), 124.7 (C1), 129.4 (C19), 129.9 (C15), 130.7 (C14), 133.1 (C18), 138.7 (C4), 145.9 (C3), 147.7 (C5), 151.4 (C17); ESIMS *m/z* 359.1 [M + 1]<sup>+</sup>; HRESIMS *m/z* 359.1856 [M + 1]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>27</sub>O<sub>5</sub>, 359.1853).

**In-Cell Western (ICW) Screen.** Extracts tested in the screen were supplied by Herb Pharm (Williams, OR). ICW was performed on M17 cells as previously described.<sup>26</sup> Briefly, M17 cells were plated in a 96-well plate with 200  $\mu$ L of complete media and treated with Herb Pharm extracts in triplicate (10% by volume). Protein levels were illuminated with rabbit antihuman tau (1:500; DAKO) and mouse antihuman glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:1500; BioDesign). Secondary infrared fluorescent antibodies were used for detection: one absorbing at 680 nm (AlexaFluor 680; Molecular Probes) and the other absorbing at 800 nm (IRDye 800 CW; Rockland, MD). Toxicity was assessed based on GAPDH immunoreactivity.

**Cell Culture and Western Blot Analysis.** HeLa cells stably expressing V5-tagged 4R0N tau were maintained under G418 selection in Opti-Mem plus 10% FBS (complete media; Invitrogen) as previously described.<sup>28</sup> IMR32, M17, and H4 cells were maintained in Opti-mem plus 10% FBS and 2% 200 mM L-glutamine (Cellgro, Mediatech, Inc., Herndon, VA). All cells were treated as indicated and were harvested as previously described.<sup>28</sup> Protein levels were determined by using the Peirce BCA kit. Western blotting was performed by running SDS-PAGE, followed by transfer onto Immobilon-P (Millipore).<sup>26,27</sup>

**Ex Vivo Slice Cultures.** Four nontransgenic 5-month-old mice were decapitated, and their brains were quickly removed. Coronal sections of 400  $\mu$ m were made using a vibratome as previously described.<sup>28,50,51</sup> Briefly, slices were allowed to recover for 1 h at RT in a 50/50 mixture of cutting solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 25 mM NaHCO<sub>3</sub>, 5 mM glucose, 0.6 mM ascorbate, 0.5 mM CaCl<sub>2</sub>, and 7 mM MgCl<sub>2</sub>) and artificial cerebral spinal fluid (ACSF; 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 25 mM NaHCO<sub>3</sub>, 25 mM glucose, 2 mM CaCl<sub>2</sub>, and 1 mM MgCl<sub>2</sub>) and then moved into ACSF at 30–32 °C for 1 h. Slices were then moved in duplicate into an oxygenated multiwell plate at 30–32 °C containing ACSF and treated with aqueous bayberry extract at the following concentrations: 9, 18, 35, 70, 105, and 140  $\mu$ g/mL. Sections were kept alive under the previously described conditions for 4 h and then snap frozen by liquid nitrogen. Sections were homogenized mechanically and analyzed as previously described.<sup>28</sup>

**Acknowledgment.** We thank Dr. P. Davies (Albert Einstein COM, NY) for PHF1 (pS396/S404) antibody. C.A.D. was supported by the Rosalinde and Arthur Gilbert Foundation/American Federation for Aging Research, CurePSP, the Alzheimer's Association, and NIA grant AG031291. B.J.B. was supported by USF's Center for Molecular Diversity in Drug Design, Discovery and Delivery.

**Supporting Information Available:** LC/MS data for F11 and commercial myricetin (2); UV, CD, <sup>1</sup>H and <sup>13</sup>C NMR spectra for isolated myricanol (3). This information is available free of charge via the Internet at <http://pubs.acs.org>.

## References and Notes

- Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H. *J. Am. Med. Assoc.* **2009**, *302*, 2557–2564.
- Gauthier, S.; Aisen, P. S.; Ferris, S. H.; Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Suhy, J.; Oh, J.; Lau, W.; Sampalis, J. *J. Nutr. Health Aging* **2009**, *13*, 550–557.
- Lyketsos, C. G.; Breitner, J. C.; Green, R. C.; Martin, B. K.; Meinert, C.; Piantadosi, S.; Sabbagh, M. *Neurology* **2007**, *68*, 1800–1808.
- Crystal, H.; Dickson, D.; Fuld, P.; Masur, D.; Scott, R.; Mehler, M.; Masdeu, J.; Kawas, C.; Aronson, M.; Wolfson, L. *Neurology* **1988**, *38*, 1682–1687.
- Braak, H.; Braak, E. *Acta Neuropathol. (Ber.)* **1991**, *82*, 239–259.
- Santacruz, K.; Lewis, J.; Spire, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K. H. *Science* **2005**, *309*, 476–481.
- Spire-Jones, T. L.; de Calignon, A.; Matsui, T.; Zehr, C.; Pitstick, R.; Wu, H. Y.; Osetek, J. D.; Jones, P. B.; Bacskai, B. J.; Feany, M. B.; Carlson, G. A.; Ashe, K. H.; Lewis, J.; Hyman, B. T. *J. Neurosci.* **2008**, *28*, 862–867.
- Roberson, E. D.; Scearce-Levie, K.; Palop, J. J.; Yan, F.; Cheng, I. H.; Wu, T.; Gerstein, H.; Yu, G. Q.; Mucke, L. *Science* **2007**, *316*, 750–754.
- Garcia, M. L.; Cleveland, D. W. *Curr. Opin. Cell Biol.* **2001**, *13*, 41–48.
- Cassimeris, L.; Spittle, C. *Int. Rev. Cytol.* **2001**, *210*, 163–226.
- Spillantini, M. G.; Murrell, J. R.; Goedert, M.; Farlow, M. R.; Klug, A.; Ghetti, B. *Proc. Natl. Acad. Sci. U. S. A.* **1998**, *95*, 7737–7741.
- Hutton, M.; Lendon, C. L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R. C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J. M.; Nowotny, P.; Heutink, P. *Nature* **1998**, *393*, 702–705.
- Hardy, J.; Orr, H. *J. Neurochem.* **2006**, *97*, 1690–1699.
- Goedert, M.; Spillantini, M. G.; Crowther, R. A.; Chen, S. G.; Parchi, P.; Tabaton, M.; Lanska, D. J.; Markesbery, W. R.; Wilhelmsen, K. C.; Dickson, D. W.; Petersen, R. B.; Gambetti, P. *Nat. Med.* **1999**, *5*, 454–457.
- Mukrasch, M. D.; Bibow, S.; Korukottu, J.; Jegannathan, S.; Biernat, J.; Griesinger, C.; Mandelkow, E.; Zweckstetter, M. *PLoS Biol.* **2009**, *7*, e34.
- Fischer, D.; Mukrasch, M. D.; Biernat, J.; Bibow, S.; Blackledge, M.; Griesinger, C.; Mandelkow, E.; Zweckstetter, M. *Biochemistry* **2009**, *48*, 10047–10055.
- Polydoro, M.; Acker, C. M.; Duff, K.; Castillo, P. E.; Davies, P. *J. Neurosci.* **2009**, *29*, 10741–10749.
- Oddo, S.; Vasilevko, V.; Caccamo, A.; Kitazawa, M.; Cribbs, D. H.; LaFerla, F. M. *J. Biol. Chem.* **2006**, *281*, 39413–39423.
- Congdon, E. E.; Necula, M.; Blackstone, R. D.; Kuret, J. *Arch. Biochem. Biophys.* **2007**, *465*, 127–135.
- Wischik, C. M.; Edwards, P. C.; Lai, R. Y.; Roth, M.; Harrington, C. R. *Proc. Natl. Acad. Sci. U. S. A.* **1996**, *93*, 11213–11218.
- Dickey, C. A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R. M.; Dunmore, J.; Ash, P.; Shoraka, S.; Zlatkovic, J.; Eckman, C. B.; Patterson, C.; Dickson, D. W.; Nahman, N. S., Jr.; Hutton, M.; Burrows, F.; Petrucelli, L. *J. Clin. Invest.* **2007**, *117*, 648–658.
- Jinwal, U. K.; Koren, J., 3rd; Borysov, S. I.; Schmid, A. B.; Abisambra, J. F.; Blair, L. J.; Johnson, A. G.; Jones, J. R.; Shults, C. L.; O'Leary, J. C., 3rd; Jin, Y.; Buchner, J.; Cox, M. B.; Dickey, C. A. *J. Neurosci.* **2010**, *30*, 591–599.
- Lim, G. P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S. A.; Cole, G. M. *J. Neurosci.* **2001**, *21*, 8370–8377.
- Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E. B.; Xie, S. X.; Joyce, S.; Li, C.; Toleikis, P. M.; Lee, V. M.; Trojanowski, J. Q. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 227–231.

- (25) Dickey, C. A.; Ash, P.; Klosak, N.; Lee, W. C.; Petrucelli, L.; Hutton, M.; Eckman, C. B. *Mol. Neurodegener.* **2006**, *1*, 6.
- (26) Dickey, C. A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C. B.; Hutton, M.; Petrucelli, L. *Curr. Alzheimer Res.* **2005**, *2*, 231–238.
- (27) Koren, J., 3rd; Jinwal, U. K.; Jin, Y.; O'Leary, J.; Jones, J. R.; Johnson, A. G.; Blair, L. J.; Abisambra, J. F.; Chang, L.; Miyata, Y.; Cheng, A. M.; Guo, J.; Cheng, J. Q.; Gestwicki, J. E.; Dickey, C. A. *J. Biol. Chem.* **2010**, *285*, 2498–2505.
- (28) Jinwal, U. K.; Miyata, Y.; Koren, J., 3rd; Jones, J. R.; Trotter, J. H.; Chang, L.; O'Leary, J.; Morgan, D.; Lee, D. C.; Shults, C. L.; Rousaki, A.; Weeber, E. J.; Zuiderweg, E. R.; Gestwicki, J. E.; Dickey, C. A. *J. Neurosci.* **2009**, *29*, 12079–12088.
- (29) Saito, A.; Sugisawa, A.; Umegaki, K. *Shokuhin Eiseigaku Zasshi* **2001**, *42*, 174–178.
- (30) Mehrdad, M.; Zebardast, M.; Abedi, G.; Koupaei, M. N.; Rasouli, H.; Talebi, M. *J. AOAC Int.* **2009**, *92*, 1035–1043.
- (31) Hakkinen, S. H.; Karenlampi, S. O.; Heinonen, I. M.; Mykkanen, H. M.; Torronen, A. R. *J. Agric. Food Chem.* **1999**, *47*, 2274–2279.
- (32) Biesaga, M.; Ochnik, U.; Pyrzynska, K. *J. Sep. Sci.* **2009**, *32*, 2835–2840.
- (33) Paul, B. D.; Rao, G. S.; Kapadia, G. J. *J. Pharm. Sci.* **1974**, *63*, 958–959.
- (34) Hollman, P. C.; Katan, M. B. *Free Radical Res.* **1999**, *31*, S75–80.
- (35) Joshi, B. S.; Pelletier, S. W.; Newton, M. G.; Lee, D.; McGaughey, G. B.; Puar, M. S. *J. Nat. Prod.* **1996**, *59*, 759–764.
- (36) Kawai, S.; Nakata, K.; Ohashi, M.; Tomoaki, N. *J. Wood Sci.* **2008**, *54*, 256–260.
- (37) Sun, D. W.; Zhao, Z. C.; Wong, H.; Foo, L. Y. *Phytochemistry* **1988**, *27*, 579–583.
- (38) Begley, M. J.; Campbell, M. V. M.; Crombie, L.; Tuck, B.; Whiting, D. A. *J. Chem. Soc. C* **1971**, 3634–3642.
- (39) Inoue, T.; Arai, Y.; Nagai, M. *Yakugaku Zasshi* **1984**, *104*, 37–41.
- (40) Takeda, Y.; Fujita, T.; Shingu, T.; Ogimi, C. *Chem. Pharm. Bull.* **1987**, *35*, 2569–2573.
- (41) Matsuda, H.; Morikawa, T.; Tao, J.; Kazuho, U.; Yoshikawa, M. *Chem. Pharm. Bull.* **2002**, *50*, 208–215.
- (42) Wang, Y.; Martinez-Vicente, M.; Kruger, U.; Kaushik, S.; Wong, E.; Mandelkow, E. M.; Cuervo, A. M.; Mandelkow, E. *Hum. Mol. Genet.* **2009**, *18*, 4153–4170.
- (43) Dajas, F.; Rivera-Megret, F.; Blasina, F.; Arredondo, F.; Abin-Carriquiry, J. A.; Costa, G.; Echeverry, C.; Lafon, L.; Heizen, H.; Ferreira, M.; Morquillo, A. *Braz. J. Med. Biol. Res.* **2003**, *36*, 1613–1620.
- (44) Choi, R. C.; Zhu, J. T.; Leung, K. W.; Chu, G. K.; Xie, H. Q.; Chen, V. P.; Zheng, K. Y.; Lau, D. T.; Dong, T. T.; Chow, P. C.; Han, Y. F.; Wang, Z. T.; Tsim, K. W. *J. Alzheimers Dis.* **2010**, *19*, 795–811.
- (45) Obregon, D. F.; Rezai-Zadeh, K.; Bai, Y.; Sun, N.; Hou, H.; Ehrhart, J.; Zeng, J.; Mori, T.; Arendash, G. W.; Shytle, D.; Town, T.; Tan, J. *J. Biol. Chem.* **2006**, *281*, 16419–16427.
- (46) Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M. B. *J. Neurochem.* **2004**, *88*, 1555–1569.
- (47) Boulton, D. W.; Walle, U. K.; Walle, T. *J. Pharm. Pharmacol.* **1999**, *51*, 353–359.
- (48) Ma, Q. L.; Yang, F.; Rosario, E. R.; Ubeda, O. J.; Beech, W.; Gant, D. J.; Chen, P. P.; Hudspeth, B.; Chen, C.; Zhao, Y.; Vinters, H. V.; Frautschy, S. A.; Cole, G. M. *J. Neurosci.* **2009**, *29*, 9078–9089.
- (49) Whiting, D. A.; Wood, A. F. *J. Chem. Soc., Perkin Trans. 1* **1980**, 623–628.
- (50) Qiu, S.; Zhao, L. F.; Korwek, K. M.; Weeber, E. J. *J. Neurosci.* **2006**, *26*, 12943–12955.
- (51) Mirmikjoo, B.; Brown, S. E.; Kim, H. F.; Marangell, L. B.; Sweatt, J. D.; Weeber, E. J. *J. Biol. Chem.* **2001**, *276*, 10888–10896.

NP100572Z